

**SMS PHARMACEUTICAL LIMITED**  
**417, Nilgiri, Aditya Enclave, Ameerpet, Hyderabad - 500 038**  
**Un-Audited Financial Results for the Quarter Ended 30th June, 2009**

S.No.	Particulars	Quarter Ended		Rs.in Lakhs
		30-06-2009	30-06-2008	Year Ended
		(Unaudited)	(Unaudited)	31-03-2009 (Unaudited)
1	(a) Net sales/Income from Operations	5,253.12	5,633.30	24,482.83
	(b) Other Operating Income	-	-	-
2	Expenditure			
	a. Increase/decrease in stock in trade and work in progress	(18.12)	(300.93)	(122.05)
	b. Consumption of raw materials	3,744.91	3,311.73	15,346.82
	c. Purchase of traded goods	-	541.53	2,574.25
	d. Employees cost	217.41	213.58	969.14
	e. Depreciation	142.06	125.94	566.34
	f. Other expenditure	868.47	839.22	3,182.42
	<b>Total - (a to f)</b>	<b>4,954.73</b>	<b>4,731.07</b>	<b>22,516.92</b>
3	Profit from Operations before Other Income, Interest and Exceptional Items (1) - (2)	298.39	902.23	1,965.91
4	Other Income	16.13	14.36	27.71
5	<b>Profit before interest &amp; Exceptional Items (3)+(4)</b>	<b>314.52</b>	<b>916.59</b>	<b>1,993.62</b>
6	Interest	167.58	207.97	1,276.11
7	<b>Profit after interest but before Exceptional Items (5)-(6)</b>	<b>146.94</b>	<b>708.62</b>	<b>717.51</b>
8	Exceptional items	-	-	-
9	<b>Profit from Ordinary Activities before Tax (7)+(8)</b>	<b>146.94</b>	<b>708.62</b>	<b>717.51</b>
10	Tax Expenses	25.00	82.25	79.30
11	<b>Net Profit from Ordinary Activities after Tax (9)-(10)</b>	<b>121.94</b>	<b>626.37</b>	<b>638.21</b>
12	Extraordinary items (net of Tax Expense )			
13	<b>Net Profit / (Loss) for the period (11)-(12)</b>	<b>121.94</b>	<b>626.37</b>	<b>638.21</b>
14	Paid-up equity share capital Rs. 10/- per share	1,001.52	1,000.22	1,001.52
15	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year			
16	Earning Per Share (EPS)			
	a) Basic and diluted EPS before Extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	1.22	6.26	6.38
	b) Basic and diluted EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualised)		6.26	6.38
17	Public Shareholding			
	- Number of Shares	4,647,066	4,634,098	4,647,066
	- Percentage of Shareholding	46.40	46.33	46.40
18	Promoters and Promoters Group Shareholding:			
	a) Pledged/Encumbered	-	-	-
	- Number of Shares	-	-	-
	- Percentage of Shares	-	-	-
	b) Non-encumbered	5,368,137	5,368,137	5,368,137
	- Number of Shares			
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100	100	100
	- Percentage of Shares (as a % of the total share capital of the company)	53.60	53.67	53.60

**Notes:**

1. The above results were subject to "Limited Review" by the Statutory Auditors and were reviewed by the Audit Committee and have been approved by the board at its meeting held on 25th July, 2009.
2. Details of amount spent out of the funds raised, by IPO and other sources, during the previous year, as per clause 43 of listing agreement are furnished below :

(Rs. in Lakhs)		
Particulars	Details	Amount
Funds Received		13,871.06
Less: Utilised		
For New Project	11,127.05	
For working capital requirements	2,044.77	
For issue expenses	637.10	13,808.92
Funds unutilised as on 30th June, 2009 and in Deposits		62.14

3. The Company's business activity falls within a single primary business segment of "Bulk Drugs". Hence segment reporting is not applicable.
4. Provision towards Income Tax for the Quarter ending 30th June, 2009 was considered to the extent of MAT Liability, taking in to consideration of benefit available U/s.35 (2AB) of Income Tax Act, 1961.
5. The effect of deferred Tax will be considered at the end of the year.
6. **There has been no change in the accounting policies adopted during the quarter ended 30th June, 2009 as compared to those followed in the preceeding financial year 2008-09**
7. Details of share holders complaints during the quarter ended 30th June, 2009 are:  
Beginning - 0; Received -3; Resolved -3 ; Pending - 0
8. Figures of previous periods have been regrouped / rearranged wherever necessary.

Place: Hyderabad  
Date : 25-07-2009

**for and on behalf of the Board  
SMS Pharmaceuticlas Limited**

**P.Ramesh Babu  
Chairman & Managing Director**